Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 1
1998 2
1999 1
2001 1
2003 1
2005 1
2006 1
2008 2
2009 1
2011 1
2012 3
2013 3
2014 1
2015 2
2016 2
2017 1
2018 2
2019 2
2020 1
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Ibuprofen therapy for cystic fibrosis lung disease: revisited.
Konstan MW. Konstan MW. Curr Opin Pulm Med. 2008 Nov;14(6):567-73. doi: 10.1097/MCP.0b013e32831311e8. Curr Opin Pulm Med. 2008. PMID: 18812834 Review.
The occurrence of gastrointestinal bleeding was higher in those treated with ibuprofen, but the incidence was very low. SUMMARY: Ibuprofen has now been shown in two long-term clinical trials to slow disease progression, with real-world clinical use supporting its effective …
The occurrence of gastrointestinal bleeding was higher in those treated with ibuprofen, but the incidence was very low. SUMMARY: Ibuprofen h …
Therapies aimed at airway inflammation in cystic fibrosis.
Konstan MW. Konstan MW. Clin Chest Med. 1998 Sep;19(3):505-13, vi. doi: 10.1016/s0272-5231(05)70096-4. Clin Chest Med. 1998. PMID: 9759552 Review.
Alternate day prednisone may be beneficial, however, unacceptable adverse effects limit long-term use. Inhaled corticosteroids are under investigation as a safer alternative. ...
Alternate day prednisone may be beneficial, however, unacceptable adverse effects limit long-term use. Inhaled corticosteroids are un …
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW; CLEAR-110 Study Group. Bilton D, et al. Among authors: konstan mw. J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16. J Cyst Fibros. 2021. PMID: 34144923 Free PMC article. Clinical Trial.
The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and efficacy of ALIS in eligible patients who completed CLEAR-108. ...Mean change from baseline in sputum density of P. aeruginosa at day 672 w …
The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and …
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL, O'Callaghan L, Pelligra C, Konstan MW, Ward A, Ishak JK, Chandler C, Liou TG. Rubin JL, et al. Among authors: konstan mw. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466618820186. doi: 10.1177/1753466618820186. Ther Adv Respir Dis. 2019. PMID: 30803355 Free PMC article.
BACKGROUND: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of lumacaftor/ivacaftor (LU …
BACKGROUND: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for …
Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States.
Thorat T, McGarry LJ, Jariwala-Parikh K, Limone B, Bonafede M, Chandarana K, Konstan MW. Thorat T, et al. Among authors: konstan mw. Pulm Ther. 2021 Jun;7(1):281-293. doi: 10.1007/s41030-021-00154-9. Epub 2021 Apr 28. Pulm Ther. 2021. PMID: 33913076 Free PMC article.
Reductions in healthcare resource utilization (HCRU) associated with ivacaftor have been observed during limited follow-up and for selected outcomes in real-world studies. This study aimed to further describe the long-term impact of ivacaftor treatment on multiple measures …
Reductions in healthcare resource utilization (HCRU) associated with ivacaftor have been observed during limited follow-up and for selected …
Treatment of airway inflammation in cystic fibrosis.
Konstan MW. Konstan MW. Curr Opin Pulm Med. 1996 Nov;2(6):452-6. Curr Opin Pulm Med. 1996. PMID: 9363184 Review.
Alternate-day prednisone (1 mg/kg) may be beneficial; however, unacceptable adverse effects limit long-term use. Inhaled corticosteroids are under investigation as a safer alternative. ...
Alternate-day prednisone (1 mg/kg) may be beneficial; however, unacceptable adverse effects limit long-term use. Inhaled corticostero …
Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.
Schechter MS, Quittner AL, Konstan MW, Millar SJ, Pasta DJ, McMullen A; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Schechter MS, et al. Among authors: konstan mw. Ann Am Thorac Soc. 2013 Jun;10(3):213-9. doi: 10.1513/AnnalsATS.201211-108OC. Ann Am Thorac Soc. 2013. PMID: 23802817
RATIONALE: Studies of pregnancy in cystic fibrosis (CF) have shown no short-term harmful effects, but there are no long-term studies on the impact of motherhood. OBJECTIVES: This study sought to evaluate longer-term physiologic and functional outcomes in wome …
RATIONALE: Studies of pregnancy in cystic fibrosis (CF) have shown no short-term harmful effects, but there are no long-term s …
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G. Konstan MW, et al. Pediatr Pulmonol. 2016 Apr;51(4):372-8. doi: 10.1002/ppul.23358. Epub 2015 Dec 27. Pediatr Pulmonol. 2016. PMID: 26709158 Clinical Trial.
CONCLUSION: Efficacy of TIP was maintained for up to seven cycles. Long-term treatment with TIP was generally safe and well tolerated with no increase in AEs....
CONCLUSION: Efficacy of TIP was maintained for up to seven cycles. Long-term treatment with TIP was generally safe and well tolerated …
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.
Mayer-Hamblett N, Nichols DP, Odem-Davis K, Riekert KA, Sawicki GS, Donaldson SH, Ratjen F, Konstan MW, Simon N, Rosenbluth DB, Retsch-Bogart G, Clancy JP, VanDalfsen JM, Buckingham R, Gifford AH. Mayer-Hamblett N, et al. Among authors: konstan mw. Ann Am Thorac Soc. 2021 Aug;18(8):1397-1405. doi: 10.1513/AnnalsATS.202010-1336SD. Ann Am Thorac Soc. 2021. PMID: 33465316 Free PMC article.
The protocol is composed of two concurrent randomized controlled trials designed to evaluate the independent short-term effects of discontinuing hypertonic saline or dornase alfa, enabling individuals on both therapies to participate in one or both trials. ...
The protocol is composed of two concurrent randomized controlled trials designed to evaluate the independent short-term effects of di …
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. Volkova N, et al. Among authors: konstan mw. J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10. J Cyst Fibros. 2020. PMID: 31196670 Free article.
BACKGROUND: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression in patients treated with ivacaftor in a real-world setting for up …
BACKGROUND: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This lon …
28 results